Pregnancy After Breast Cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study.


Journal

JAMA
ISSN: 1538-3598
Titre abrégé: JAMA
Pays: United States
ID NLM: 7501160

Informations de publication

Date de publication:
07 Dec 2023
Historique:
pmc-release: 07 06 2024
medline: 7 12 2023
pubmed: 7 12 2023
entrez: 7 12 2023
Statut: aheadofprint

Résumé

Young women with breast cancer who have germline pathogenic variants in BRCA1 or BRCA2 face unique challenges regarding fertility. Previous studies demonstrating the feasibility and safety of pregnancy in breast cancer survivors included limited data regarding BRCA carriers. To investigate cumulative incidence of pregnancy and disease-free survival in young women who are BRCA carriers. International, multicenter, hospital-based, retrospective cohort study conducted at 78 participating centers worldwide. The study included female participants diagnosed with invasive breast cancer at age 40 years or younger between January 2000 and December 2020 carrying germline pathogenic variants in BRCA1 and/or BRCA2. Last delivery was October 7, 2022; last follow-up was February 20, 2023. Pregnancy after breast cancer. Primary end points were cumulative incidence of pregnancy after breast cancer and disease-free survival. Secondary end points were breast cancer-specific survival, overall survival, pregnancy, and fetal and obstetric outcomes. Of 4732 BRCA carriers included, 659 had at least 1 pregnancy after breast cancer and 4073 did not. Median age at diagnosis in the overall cohort was 35 years (IQR, 31-38 years). Cumulative incidence of pregnancy at 10 years was 22% (95% CI, 21%-24%), with a median time from breast cancer diagnosis to conception of 3.5 years (IQR, 2.2-5.3 years). Among the 659 patients who had a pregnancy, 45 (6.9%) and 63 (9.7%) had an induced abortion or a miscarriage, respectively. Of the 517 patients (79.7%) with a completed pregnancy, 406 (91.0%) delivered at term (≥37 weeks) and 54 (10.4%) had twins. Among the 470 infants born with known information on pregnancy complications, 4 (0.9%) had documented congenital anomalies. Median follow-up was 7.8 years (IQR, 4.5-12.6 years). No significant difference in disease-free survival was observed between patients with or without a pregnancy after breast cancer (adjusted hazard ratio, 0.99; 95% CI, 0.81-1.20). Patients who had a pregnancy had significantly better breast cancer-specific survival and overall survival. In this global study, 1 in 5 young BRCA carriers conceived within 10 years after breast cancer diagnosis. Pregnancy following breast cancer in BRCA carriers was not associated with decreased disease-free survival. ClinicalTrials.gov Identifier: NCT03673306.

Identifiants

pubmed: 38059899
pii: 2812828
doi: 10.1001/jama.2023.25463
pmc: PMC10704340
doi:

Banques de données

ClinicalTrials.gov
['NCT03673306']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Investigateurs

Evandro de Azambuja (E)
Chiara Molinelli (C)
Marianne Paesmans (M)
Lieveke Ameye (L)
Frédéric Amant (F)
Hilde Brems (H)
Sileny Han (S)
Sigrid Hatse (S)
Ines Nevelsteen (I)
Patrick Neven (P)
Ann Smeets (A)
Chantal Van Rompuy (C)
Hans Wildiers (H)
Francois Duhoux (F)
Federica Giugliano (F)
Carmen Criscitiello (C)
Roberto Borea (R)
Luca Arecco (L)
Alessandra Chirco (A)
Federica Bini (F)
Marta Venturelli (M)
Laura Cortesi (L)
Riccardo Ponzone (R)
Nicoletta Tomasi Cont (N)
Judith Balmaña (J)
Rossella Graffeo (R)
Helena Luna Pais (H)
Alejandro Mohar (A)
Tamara Palacios (T)
Lucia Da Ros (L)
Gianmaria Miolo (G)
Mattia Garutti (M)
Brenno Pastò (B)
Simon Spazzapan (S)
Alessandra Viel (A)
Alejandro Pérez-Fidalgo (A)
Renata Colombo Bonadio (R)
Tamar Peretz-Yablonski (T)
Chiara Annunziata Pasqualina Anghelone (CAP)
Angelica Della Valle (A)
Maria Campanella (M)
Valentina Guarneri (V)
Raphaelle Bas (R)
Pierre-Etienne Heudel (PE)
Olivier Tredan (O)
Solenne de Talouet (S)
Valérie Bonadona (V)
Christine Lasset (C)
Marion Acheritogaray (M)
Claire Senechal (C)
Monica Mariño (M)
Octavi Córdoba (O)
Didi Feldman (D)
Romina I Pesce (RI)
Carol Allemand (C)
Cecilia Riggi (C)
Maria Belen Iriarte (MB)
Alfonso Cortés Salgado (A)
Javier Cortes (J)
María Gion (M)
Cristina Saavedra (C)
Adela Rodriguez (A)
Barbara Adamo (B)
Aleix Prat (A)
Anna Hester (A)
Sofia Dunckelmann (S)
Nadia Harbeck (N)
Maximilian Marhold (M)
Rupert Bartsch (R)
Constantin Mannsbarth (C)
Lazar Popovic (L)
Ivana Božović-Spasojević (I)
Ana Krivokuca (A)
Marija Dimitrijevic (M)
Luca Visani (L)
Beatrice Bettazzi (B)
Lorenzo Livi (L)
Caterina Sposetti (C)
Valentina Sini (V)
Alessia Rognone (A)
Giampaolo Bianchini (G)
Maria Grazia Patricelli (MG)
Emanuela Rabaiotti (E)
Oreste Gentilini (O)
Andrea Fontana (A)
Giulia Acconci (G)
Erica Baldacci (E)
Giulia Bianchini (G)
Mirco Pistelli (M)
Sabine Linn (S)
Sieta Kleiterp (S)
Daoud A Moha (DA)
Rajiv Sarin (R)
Anberson Sekar (A)
Francesco Atzori (F)
Francesco Loi (F)
Mariele Dessì (M)
Sarah O'Connor (S)
Stephanie Nesci (S)
Paul James (P)
Chris Michael (C)
Fergus J Couch (FJ)
Janet E Olson (JE)
Nicole L Larson (NL)
Siddhartha Yadav (S)
Nerea Lopetegui (N)
Lisa A Carey (LA)
Yara Abdou (Y)
Paola Zagami (P)
Roberta Di Rocco (R)
Margherita Baldassarri (M)
Carmelo Bengala (C)
Elene Mariamidze (E)
Stephanie L Graff (SL)
Stephanie A Haddad (SA)
Emma Safran (E)
Leonor Vasconcelos de Matos (L)
Arlindo Ferreira (A)
Serena Negri (S)
Cristina Dell'Oro (C)
Alessandra Inzoli (A)
Clarissa Costa (C)
Liliana Marchetta (L)
Maryam Lustberg (M)
Deanna Blansky (D)
June Jeon (J)
Norin Ansari (N)
Dione Aguilar-Y-Mendez (D)
Teresa K Woodruff (TK)
Monique Swain (M)
Madison Miller (M)
Richard Leach (R)
Alessandra Fabi (A)
Antonella Palazzo (A)
Ida Paris (I)
Joanna Kufel-Grabowska (J)
Agnieszka Synowiec (A)
Miriam Hancinova (M)
Lukas Tarbaj (L)
Emir Sokolović (E)
Semir Bešlija (S)
Timur Cerić (T)
Berisa Hasanbegović (B)
William D Foulkes (WD)
Manuel A Bianchi (MA)
Pablo Tolosa (P)
Laura Alvaro (L)
Louise Eriksson Bergman (L)
Nicoleta Antone (N)
Cristina Damian (C)

Références

BMJ. 2019 Mar 20;364:l869
pubmed: 30894356
J Clin Oncol. 2021 Oct 10;39(29):3293-3305
pubmed: 34197218
Lancet Oncol. 2023 Oct;24(10):e415-e423
pubmed: 37797647
Ann Oncol. 2023 Jan;34(1):33-47
pubmed: 36307055
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Cancer. 2018 Nov 15;124(22):4401-4407
pubmed: 30403424
Hum Reprod. 2020 Aug 1;35(8):1864-1874
pubmed: 32604417
Int J Cancer. 2005 Dec 20;117(6):988-91
pubmed: 15986445
NCHS Data Brief. 2023 Aug;(477):1-8
pubmed: 37642980
Sci Rep. 2022 Feb 1;12(1):1658
pubmed: 35105904
N Engl J Med. 2023 May 4;388(18):1645-1656
pubmed: 37133584
Breast Care (Basel). 2020 Apr;15(2):148-156
pubmed: 32398983
Nat Cancer. 2022 Aug;3(8):1-13
pubmed: 36008687
JCO Oncol Pract. 2022 Mar;18(3):165-168
pubmed: 34606330
Fertil Steril. 2020 Jun;113(6):1251-1260.e1
pubmed: 32331767
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
Fertil Steril. 2017 Jan;107(1):243-252.e5
pubmed: 27887709
Ann Oncol. 2022 Nov;33(11):1097-1118
pubmed: 35934170
Am J Perinatol. 2017 Feb;34(3):217-222
pubmed: 27398707
J Clin Oncol. 2018 Jul 1;36(19):1994-2001
pubmed: 29620997
Breast Cancer Res. 2003;5(5):R121-8
pubmed: 12927042
J Natl Cancer Inst. 2014 Jun;106(6):dju091
pubmed: 24824314
J Clin Oncol. 2021 Jun 20;39(18):2016-2024
pubmed: 33891474
J Clin Oncol. 2014 Apr 10;32(11):1151-6
pubmed: 24567428
Cancer Epidemiol. 2014 Feb;38(1):1-8
pubmed: 24332935
BMC Med. 2021 Sep 10;19(1):205
pubmed: 34503502
Reprod Biomed Online. 2022 Jun;44(6):1031-1044
pubmed: 35525718
J Clin Oncol. 2020 Sep 10;38(26):3012-3023
pubmed: 32673153
Ann Oncol. 2020 Dec;31(12):1664-1678
pubmed: 32976936
ESMO Open. 2023 Oct 23;8(6):102031
pubmed: 37879234
Lancet Oncol. 2018 Feb;19(2):169-180
pubmed: 29337092

Auteurs

Matteo Lambertini (M)

Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genova, Italy.
Department of Medical Oncology, U. O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.

Eva Blondeaux (E)

U. O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.

Elisa Agostinetto (E)

Breast Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium.

Anne-Sophie Hamy (AS)

Department of Medical Oncology, Universite Paris Cité, Institut Curie, Paris, France.

Hee Jeong Kim (HJ)

Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Antonio Di Meglio (A)

Cancer Survivorship Program-Molecular Predicitors and New Targets in Oncology, INSERM Unit 981, Gustave Roussy, Villejuif, France.

Rinat Bernstein Molho (R)

Susanne Levy Gertner Oncogenetics Unit, Danek Gertner Institute of Human Genetics, Chaim Sheba Medical Center Affiliated to Tel Aviv University, Tel Hashomer, Israel.

Florentine Hilbers (F)

Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.

Katarzyna Pogoda (K)

Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.

Estela Carrasco (E)

Hereditary Cancer Genetics Unit, Medical Oncology Department, Vall d´Hebron University Hospital, Vall d´Hebron Institute of Oncology, Barcelona, Spain.

Kevin Punie (K)

Department of General Medical Oncology and Multidisciplinary Breast Center, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.

Jyoti Bajpai (J)

Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.

Michail Ignatiadis (M)

Breast Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Brussels, Belgium.

Halle C F Moore (HCF)

Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio.

Kelly-Anne Phillips (KA)

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.
Centre for Epidemiology and Biostatistics, School of Population and Global Health, The University of Melbourne, Melbourne, Victoria, Australia.

Angela Toss (A)

Department of Oncology and Haematology, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.

Christine Rousset-Jablonski (C)

Department of Surgery, Leon Berard Cancer Center, Lyon, France.

Fedro A Peccatori (FA)

Gynecologic Oncology Department, European Institute of Oncology (IRCCS), Milan, Italy.

Tiphaine Renaud (T)

Cancer Genetics Unit, Bergonie Institute, Bordeaux, France.

Alberta Ferrari (A)

Hereditary Breast and Ovarian Cancer Unit and General Surgery 3-Senology, Surgical Department, Fondazione IRCCS Policlinico San Matteo, and University of Pavia, Pavia, Italy.

Shani Paluch-Shimon (S)

Breast Oncology Unit, Sharett Institute of Oncology, Hadassah University Hospital, and Faculty of Medicine, Hebrew University, Jerusalem, Israel.

Robert Fruscio (R)

UO Gynecology, Department of Medicine and Surgery, University of Milan-Bicocca, IRCCS San Gerardo dei Tintori, Monza, Italy.

Wanda Cui (W)

Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Victoria, Australia.

Stephanie M Wong (SM)

Stroll Cancer Prevention Centre, Jewish General Hospital, and McGill University Medical School, Montreal, Quebec, Canada.

Claudio Vernieri (C)

Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
IFOM ETS, AIRC Institute of Molecular Oncology, Milan, Italy.

Kathryn J Ruddy (KJ)

Department of Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota.

Maria Vittoria Dieci (MV)

Dipartimento di Scienze Chirurgiche, Oncologiche, e Gastroenterologiche, Università di Padova, Padova, Italy.
Oncologia 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.

Alexios Matikas (A)

Department of Oncology/Pathology, Karolinska Institute, and Breast Center, Karolinska University Hospital, Stockholm, Sweden.

Mariya Rozenblit (M)

Department of Medical Oncology, Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut.

Cynthia Villarreal-Garza (C)

Breast Cancer Center, Hospital Zambrano Hellion-TecSalud, Tecnologico de Monterrey, Monterrey, Mexico.

Laura De Marchis (L)

Department of Radiological, Oncological, and Pathological Sciences, Sapienza University of Rome, Rome, Italy.
Division of Oncology, Department of Hematology, Oncology, and Dermatology, Umberto 1 University Hospital, Rome, Italy.

Lucia Del Mastro (L)

Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova, Genova, Italy.
Department of Medical Oncology, U. O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.

Fabio Puglisi (F)

Department of Medical Oncology, Centro di Riferimento Oncologico di Avano (CRO) IRCCS, Aviano, Italy.
Department of Medicine, University of Udine, Udine, Italy.

Maria Del Pilar Estevez-Diz (M)

Department of Radiology and Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

Kenny A Rodriguez-Wallberg (KA)

Department of Oncology-Pathology, Laboratory of Translational Fertility Preservation, Karolinska Institute, Stockholm, Sweden.
Department of Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden.

Bela Mrinakova (B)

First Department of Oncology, Comenius University and St Elisabeth Cancer Institute, Bratislava, Slovakia.

Sarah Meister (S)

Department of Obstetrics and Gynecology, Ludwig Maximilian University (LMU) Hospital, LMU Munich, Germany.

Luca Livraghi (L)

Department of Medical Oncology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
Department of Medical Oncology, Hospital of Prato, Azienda USL Toscana Centro, Italy.

Florian Clatot (F)

Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.

Rinat Yerushalmi (R)

Department of Medical Oncology, Davidoff Center, Rabin Medical Center, Petah Tikva, Tel Aviv University, Tel Aviv, Israel.

Carmine De Angelis (C)

Department of Medical Oncology, University of Naples Federico II, Napoli, Italy.

Rodrigo Sánchez-Bayona (R)

Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.

Icro Meattini (I)

Department of Experimental and Clinical Biomedical Sciences M. Serio, University of Florence, and Radiation Oncology Unit, Oncology Department, Florence University Hospital, Florence, Italy.

Natalia Cichowska-Cwalinska (N)

Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.
Early Phase Clinical Trials Centre, Medical University of Gdańsk, Gdańsk, Poland.

Martine Berlière (M)

Department of Medical Oncology and Breast Surgery, Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCL), Brussels, Belgium.

Mahmoud Salama (M)

Oncofertility Consortium and Department of Obstetrics, Gynecology, and Reproductive Biology, Michigan State University, East Lansing.

Ugo De Giorgi (U)

Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy.

Amir Sonnenblick (A)

Oncology Division, Tel Aviv Sourasky Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Camila Chiodi (C)

Cancer Survivorship Program-Molecular Predicitors and New Targets in Oncology, INSERM Unit 981, Gustave Roussy, Villejuif, France.

Young-Jin Lee (YJ)

Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Camille Maria (C)

Department of Medical Oncology, Universite Paris Cité, Institut Curie, Paris, France.

Hatem A Azim (HA)

Breast Cancer Center, Hospital Zambrano Hellion-TecSalud, Tecnologico de Monterrey, Monterrey, Mexico.
Cairo Oncology Center, Cairo, Egypt.

Luca Boni (L)

U. O. Epidemiologia Clinica, IRCCS Ospedale Policlinico San Martino, Genova, Italy.

Ann H Partridge (AH)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Classifications MeSH